AMP 2019 Presentation

NeuMoDx™ Molecular recently presented the evaluation of DiaSorin Molecular Enterovirus (EV) Primer Pair and Cytomegalovirus (CMV) Primer Pair in Laboratory Developed Test (LDT) Implementation on the open, random-access NeuMoDx™ 288 Molecular System at the Association for Molecular Pathology’s conference held in Baltimore Maryland. Michelle Mastronardi (Director, Systems Integration at NeuMoDx Molecular), along with Stephen Young, Ph.D. (Director of Research and Clinical Trials TriCore Reference Laboratories), keynoted our workshop, speaking to the work they have performed utilizing our system firsthand and presenting their experiences. To view our latest presentation, please fill out the form below.


    We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

    To learn more, click here.